IBRX
Price
$2.56
Change
-$0.07 (-2.65%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
2.33B
36 days until earnings call
JAGX
Price
$2.49
Change
-$0.03 (-1.19%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
3.35M
Interact to see
Advertisement

IBRX vs JAGX

Header iconIBRX vs JAGX Comparison
Open Charts IBRX vs JAGXBanner chart's image
ImmunityBio
Price$2.56
Change-$0.07 (-2.65%)
Volume$117.04K
Capitalization2.33B
Jaguar Health
Price$2.49
Change-$0.03 (-1.19%)
Volume$239
Capitalization3.35M
IBRX vs JAGX Comparison Chart in %
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBRX vs. JAGX commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Hold and JAGX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (IBRX: $2.64 vs. JAGX: $2.52)
Brand notoriety: IBRX and JAGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 51% vs. JAGX: 58%
Market capitalization -- IBRX: $2.33B vs. JAGX: $3.35M
IBRX [@Biotechnology] is valued at $2.33B. JAGX’s [@Biotechnology] market capitalization is $3.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 1 FA rating(s) are green whileJAGX’s FA Score has 1 green FA rating(s).

  • IBRX’s FA Score: 1 green, 4 red.
  • JAGX’s FA Score: 1 green, 4 red.
According to our system of comparison, IBRX is a better buy in the long-term than JAGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 4 TA indicator(s) are bullish while JAGX’s TA Score has 3 bullish TA indicator(s).

  • IBRX’s TA Score: 4 bullish, 6 bearish.
  • JAGX’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, JAGX is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а -4.35% price change this week, while JAGX (@Biotechnology) price change was -6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

IBRX is expected to report earnings on Aug 06, 2025.

JAGX is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.33B) has a higher market cap than JAGX($3.35M). IBRX YTD gains are higher at: 3.125 vs. JAGX (-90.020). JAGX has higher annual earnings (EBITDA): -37.39M vs. IBRX (-264M). IBRX has more cash in the bank: 61.6M vs. JAGX (5.69M). JAGX has less debt than IBRX: JAGX (38.3M) vs IBRX (526M). IBRX has higher revenues than JAGX: IBRX (31.2M) vs JAGX (11.6M).
IBRXJAGXIBRX / JAGX
Capitalization2.33B3.35M69,531%
EBITDA-264M-37.39M706%
Gain YTD3.125-90.020-3%
P/E RatioN/A0.01-
Revenue31.2M11.6M269%
Total Cash61.6M5.69M1,083%
Total Debt526M38.3M1,373%
FUNDAMENTALS RATINGS
IBRX vs JAGX: Fundamental Ratings
IBRX
JAGX
OUTLOOK RATING
1..100
6753
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6298
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (4) in the Biotechnology industry is in the same range as JAGX (28) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

IBRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

IBRX's SMR Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

IBRX's Price Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for JAGX (98) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew somewhat faster than JAGX’s over the last 12 months.

IBRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that IBRX’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXJAGX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 23 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DPREX12.730.04
+0.32%
Macquarie Global Listed Real Assets A
LVOFX18.89N/A
N/A
Lord Abbett Value Opportunities F
RSEGX53.54N/A
N/A
Victory RS Small Cap Growth A
RERGX60.58N/A
N/A
American Funds EUPAC R6
JSERX53.43N/A
N/A
JPMorgan Small Cap Equity R5

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-2.22%
AXON - IBRX
48%
Loosely correlated
+1.14%
RXRX - IBRX
42%
Loosely correlated
+0.70%
ARRY - IBRX
41%
Loosely correlated
-8.39%
CLRB - IBRX
41%
Loosely correlated
-10.00%
QTTB - IBRX
39%
Loosely correlated
+2.76%
More

JAGX and

Correlation & Price change

A.I.dvisor tells us that JAGX and RNAZ have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and RNAZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
+0.80%
RNAZ - JAGX
31%
Poorly correlated
-2.13%
DVHGF - JAGX
27%
Poorly correlated
N/A
SNPX - JAGX
26%
Poorly correlated
+29.86%
SLNO - JAGX
26%
Poorly correlated
+0.64%
ACET - JAGX
26%
Poorly correlated
-2.49%
More